Cramer says Apple and Eli Lilly still have room to run after post-earnings rallies

Apple rose more than 4% after reporting second-quarter revenue of $111.2 billion, up 17% year over year and ahead of the $109.7 billion estimate, while issuing very strong guidance and highlighting an all-time high installed base above 2.5 billion devices. Eli Lilly added another 3% after a nearly 10% post-earnings jump Thursday, following a 56% revenue surge to $19.8 billion and what Jim Cramer called an extraordinary quarter. The S&P 500 set a fresh intraday high as enthusiasm around Apple and other Mag Seven names supported broader risk-on sentiment, while oil prices fell on renewed hopes of a peace agreement involving Iran and the United States.

Analysis

This tape is less about one-off beats and more about a reflexive re-rating of mega-cap duration assets. When the largest index weights simultaneously clear earnings and guidance hurdles, passive and factor flows can create a self-reinforcing squeeze: systematic trend, CTA, and risk-parity exposures all get nudged higher, which can keep a handful of names levitating even if breadth stays mediocre. The immediate second-order effect is pressure on under-owned large-cap defensives and cash-rich software/hardware suppliers that may now trade at a discount to growth despite similar balance-sheet quality.

Apple’s strength matters beyond the headline because it restores confidence in the consumer-tech install base as a monetization engine, not just a hardware cycle. That tends to lift the entire ecosystem: app monetizers, device accessory chains, and semiconductor names tied to premium device demand should benefit over the next 1-3 quarters if upgrade cycles and services attach rates hold. The main risk is that the market extrapolates too far from a single quarter into a full re-acceleration narrative; if the next handset/data-point disappoints, multiple compression could be abrupt because positioning has likely moved from skeptical to crowded in only a few sessions.

Lilly’s move is more interesting because it suggests investors are still underpricing the durability of GLP-1 capacity expansion and the knock-on effect on payer adoption. If the market starts treating this as a multi-year category winner rather than a one-quarter beat, then contract manufacturers, fill-finish capacity, and select obesity-adjacent suppliers may see a second leg higher. The contrarian risk is policy and supply normalization: any sign of pricing pressure, reimbursement pushback, or faster-than-expected competitive supply growth could cap upside once the initial momentum fades.

The geopolitical/oil piece creates an important cross-asset setup: softer crude is a tax cut for cyclicals and a tailwind for margin-sensitive consumer discretionary, while it removes some urgency from energy positioning. If the oil move persists for weeks, energy equities may underperform even if broader indices stay firm, especially after recent relative strength. Near term, this favors staying long quality megacap growth while fading the most extended energy beta, but not chasing the latter if crude re-firms on any breakdown in diplomacy.

Key Decisions for Investors

• Stay long AAPL into the next 2-6 weeks, but use strength to sell upside calls against core stock if implied vol remains elevated; upside is still open, but the first-order move likely becomes a grind rather than a gap.
• Add to GOOGL/AMZN versus META/MSFT on a 1-3 month horizon; the market is rewarding clean monetization and better incremental confidence, while the laggards may remain range-bound until the next proof point.
• Initiate a long LLY / short large-cap pharma basket pair for 1-2 quarters; Lilly has the best odds of continuing to compound on execution, but size modestly because payer/policy headlines can reverse momentum quickly.
• Fade energy beta tactically over 1-4 weeks via short XLE or selective E&P underweights against long consumer/sensitive cyclicals; the trade works only if crude weakness persists and diplomatic headlines keep pressure on oil.